- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01598194
Comparison of a Novel 22-gauge Core Biopsy Needle
Prospective Comparison of a Novel 22-gauge Core Biopsy Needle With Reverse Bevel Design to a Standard Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) Needle for Diagnosis of Solid Pancreatic Mass Lesions
Study Overview
Status
Intervention / Treatment
Detailed Description
An endoscopic ultrasound-guided needle biopsy or FNA is a special endoscopic procedure used to sample lesions within or next to the digestive tract, including the pancreas. The needle is used to collect material for diagnosis. A special lighted, flexible tube called an endoscope is inserted through the mouth, into the stomach and small intestine. The endoscope also has an ultrasound probe at its tip which can be used to see the pancreas, which is located behind the stomach. The doctor will then use the ultrasound to guide the needle biopsy or FNA.
In this procedure, an average of 4 needle passes (needle sticks) is needed to collect enough tissue for diagnosis. However, the number of passes can be higher or lower, depending on the individual lesion and success of the needle passes.
If participant agrees to take part in this study, 2 different needles (the standard straight hollow-core needle and the new EchoTip® Procore™ needle) will be used to sample the pancreas lesion. Two (2) passes will be performed with each needle type and compared. If additional passes are needed for diagnosis, they will not be included in this study. After the first set of needle passes, the doctor may decide that more passes are needed.
Final test results will be taken from the diagnostic results from each needle pass. The results from both types of the needle will be included in the participant's medical record.
This is an investigational study. All needles used in this study are FDA approved and commercially available. Comparing the needles is investigational.
Up to 60 participants will take part in this study. All will be enrolled at MD Anderson.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient age 18 years and older.
- All patients referred for EUS FNA of endoscopically accessible solid pancreatic lesions.
Exclusion Criteria:
- Unable to obtain informed consent.
- Unable to tolerate the procedure.
- Women with known pregnancy at time.
- Patient age less than 18 years of age.
- Bleeding diathesis
- Cystic pancreatic lesions
- Lesion not accessible by EUS guided FNA
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Novel 22-gauge Core Biopsy Needle Standard Biopsy Needle
The 22-gauge core biopsy needle with reverse bevel design (EchoTip® Procore™) will be compared prospectively to the standard straight hollow-core 22-gauge or 25-gauge FNA needle already used in our clinical practice for the diagnosis of solid pancreatic lesions.
|
Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle.
All passes will be taken from a single lesion and from the same endoscopic location.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Diagnostic Adequacy Scores With SST vs. CST for Cytologic Diagnosis Using a 22G Core Needle.
Time Frame: Each EGD EUS-FNA endoscopy procedure takes about 1 hour. Each needle pass takes about 1-2 minutes.
|
The main outcome measure of the study was the diagnostic adequacy of the 22Gpc using SST and CST.
The cytologic diagnostic adequacy of 22Gpc was also compared to the standard 25 G needle.
Each participant underwent 4 study passes, 2 passes with a standard 25 G needle using SST, plus a random assignment to one of two groups for 2 passes with the 22Gpc (1 pass for cytologic and 1 pass for histologic analysis) using SST (group 1) or CST (group 2).
Diagnostic adequacy was defined as the ability to procure cytological aspirates or histological core tissue samples that were sufficient for diagnostic interpretation.
|
Each EGD EUS-FNA endoscopy procedure takes about 1 hour. Each needle pass takes about 1-2 minutes.
|
Comparison of Diagnostic Adequacy Scores With SST vs. CST for Histologic Diagnosis Using a 22G Core Needle.
Time Frame: Each EGD EUS-FNA endoscopy procedure takes about 1 hour. Each needle pass takes about 1-2 minutes
|
The main outcome measure of the study was the diagnostic adequacy of the 22Gpc using SST versus CST on EUS-FNA.
The cytologic diagnostic adequacy of 22Gpc was also compared to the standard 25G needle.
Diagnostic adequacy was defined as the ability to procure cytological aspirates or histological core tissue samples that were sufficient for diagnostic interpretation.
Two cytopathologists, blinded to needle type and technique, reviewed and graded all the study slides.
Cytologic diagnostic adequacy of each pass was graded on a semiquantitative scale from 0 to 3 based on sample cellularity.
A score of 2 (estimated cell count > 500 cells) or 3 (estimated cell count > 1000 cells) was considered adequate for diagnosis; a score of 3 was most desirable.
A score < 2 was considered inadequate.
Histologic diagnostic adequacy was graded as either an adequate (score 2 or 3) or inadequate specimen for diagnosis.
|
Each EGD EUS-FNA endoscopy procedure takes about 1 hour. Each needle pass takes about 1-2 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Diagnostic Adequacy of Single Pass With 22G Core Needle and Standard 25G Needle for Cytologic Diagnosis
Time Frame: Each EGD EUS-FNA endoscopy procedure takes about 1 hour. Each needle pass takes about 1-2 minutes
|
The cytologic diagnostic adequacy of 22Gpc was compared to the standard 25G needle.
Diagnostic adequacy was defined as the ability to procure cytological aspirates that were sufficient for diagnostic interpretation.
Two cytopathologists, blinded to needle type and technique, reviewed and graded all the study slides.
Cytologic diagnostic adequacy of each pass was graded on a semiquantitative scale from 0 to 3 based on sample cellularity.
A score of 2 (estimated cell count > 500 cells) or 3 (estimated cell count > 1000 cells) was considered adequate for diagnosis; a score of 3 was most desirable.
A score < 2 was considered inadequate.
|
Each EGD EUS-FNA endoscopy procedure takes about 1 hour. Each needle pass takes about 1-2 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brian Weston, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-0907
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasm of Pancreas
-
Hospital Universitari de BellvitgeCompletedMalignant Neoplasm of Head of PancreasSpain
-
Taiho Oncology, Inc.Quintiles, Inc.CompletedSecondary Malignant Neoplasm of Pancreas
-
Tata Medical CenterCompletedMalignant Neoplasm of Oropharynx Stage III | Malignant Neoplasm of Larynx Stage III | Malignant Neoplasm of Hypopharynx Stage III | Malignant Neoplasm of Oropharynx Stage IVa | Malignant Neoplasm of Oropharynx Stage IVb | Malignant Neoplasm of Larynx Stage IV | Malignant Neoplasm of Hypopharynx... and other conditionsIndia
-
Asan Medical CenterOlympusCompletedBenign Neoplasm of Body of Pancreas | Benign Neoplasm of Tail of Pancreas
-
David BartlettNational Cancer Institute (NCI)CompletedPeritoneal Carcinomatosis | Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface | Malignant Peritoneal MesotheliomaUnited States
-
Seoul National University HospitalSamsung Medical Center; Seoul St. Mary's Hospital; Asan Medical Center; Seoul National... and other collaboratorsRecruitingPancreas Neoplasm Malignant ResectableKorea, Republic of
-
Sahlgrenska University Hospital, SwedenThe Swedish Research Council; Sjöbergstiftelsen; VGregionRecruitingGynecologic Cancer | Malignant Neoplasm | Malignant Neoplasm of Large Intestine | Malignant Neoplasm of Colon | Malignant Neoplasm of Prostate | Malignant Neoplasm of Rectum | Malignant Neoplasm of Anus | Malignant Neoplasm of Urinary Bladder | Malignant Neoplasm of Cervix | Malignant Neoplasm of OvarySweden
-
Barbara Ann Karmanos Cancer InstituteCompletedColorectal Cancer | Pancreatic Cancer | Colon Carcinoma | Cancer of Pancreas | Pancreatic Neoplasm | Malignant Neoplasm of Large Intestine | Cancer of Colon | Malignant Tumor of ColonUnited States
-
Henry Ford Health SystemCompletedPancreas Neoplasm Malignant ResectableUnited States
-
Verastem, Inc.RecruitingMetastatic Cancer | Pancreas Cancer | Neoplasms Pancreatic | KRAS Activating Mutation | Malignant Neoplasm of PancreasUnited States
Clinical Trials on Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle
-
Samsung Medical CenterCompletedPancreatic NeoplasmsKorea, Republic of
-
Medical University of South CarolinaJohns Hopkins University; University of North Carolina; Cook Endoscopy; Thoraxklinik-Heidelberg...CompletedQuantity of Tissue Obtained | Quality of Tissue Obtained | Ease of Use of 22-gauge ProCore EBUS Needles and the Standard 22-gauge NeedlesUnited States
-
Samsung Medical CenterOlympusCompletedPancreatic CancerKorea, Republic of
-
AdventHealthCompletedHepatic Cancer | Hepatic Carcinoma | Hepatic NeoplasmUnited States
-
Philips HealthcareWithdrawnProstate CancerUnited States
-
Modarres HospitalCompleted
-
Postgraduate Institute of Medical Education and...All India Institute of Medical Sciences, New Delhi; Rajiv Gandhi Cancer Institute... and other collaboratorsCompleted
-
Shandong Cancer Hospital and InstituteUnknown
-
Yale UniversityRothman Institute OrthopaedicsCompletedPain | Needle InjuryUnited States
-
AdventHealthCompletedPancreatic CancerUnited States